These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF. Ortaldo JR, Winkler-Pickett R, Morgan AC, Woodhouse C, Kantor R, Reynolds CW. J Immunol; 1987 Nov 01; 139(9):3159-65. PubMed ID: 3668253 [Abstract] [Full Text] [Related]
23. Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. Zambello R, Trentin L, Agostini C, Chisesi T, Vespignani M, Pizzolo G, Pandolfi F, Ensoli F, Semenzato G. Leuk Res; 1989 Nov 01; 13(4):315-22. PubMed ID: 2497276 [Abstract] [Full Text] [Related]
24. Identification of human natural killer soluble cytotoxic factors (NKCF) derived from NK-enriched lymphocyte populations: specificity of generation and killing. Farram E, Targan SR. J Immunol; 1983 Mar 01; 130(3):1252-6. PubMed ID: 6822733 [Abstract] [Full Text] [Related]
25. Studies of human natural killer cytotoxic factor (NKCF): characterization and analysis of its mode of action. Ortaldo JR, Blanca I, Herberman RB. Adv Exp Med Biol; 1985 Mar 01; 184():203-20. PubMed ID: 3898750 [Abstract] [Full Text] [Related]
27. An inducer of NKCF (NK cytotoxic factor) release: localization on target-cell membrane and initial characterization. Reiter Z, Loyter A, Nussbaum O, Rubinstein M. Cell Immunol; 1992 Jul 01; 142(2):370-84. PubMed ID: 1377986 [Abstract] [Full Text] [Related]
28. Studies on the mechanism of the human natural killer cell lethal hit: analysis of the mechanism of protease inhibition of the lethal hit. Hiserodt JC, Britvan L, Targan SR. J Immunol; 1983 Dec 01; 131(6):2705-9. PubMed ID: 6358352 [Abstract] [Full Text] [Related]
29. Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon. Degliantoni G, Murphy M, Kobayashi M, Francis MK, Perussia B, Trinchieri G. J Exp Med; 1985 Nov 01; 162(5):1512-30. PubMed ID: 3932579 [Abstract] [Full Text] [Related]
31. Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin. Bialas T, Kolitz J, Levi E, Polivka A, Oez S, Miller G, Welte K. Cancer Res; 1988 Feb 15; 48(4):891-8. PubMed ID: 3257413 [Abstract] [Full Text] [Related]
34. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor. Chang WC, Hsiao MH, Pattengale PK. Nat Immun Cell Growth Regul; 1991 Feb 15; 10(2):57-70. PubMed ID: 1881400 [Abstract] [Full Text] [Related]
36. Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). Marubayashi M, Solana R, Ramirez R, Aranda E, Galan F, Peña J. Br J Cancer; 1991 Jun 15; 63(6):893-6. PubMed ID: 1906292 [Abstract] [Full Text] [Related]
37. Mechanism of inhibition of natural killing by a glycopeptide isolated from the K562 plasma membrane. Targan S, Decker JM, Ades EW. Nat Immun Cell Growth Regul; 1991 Jun 15; 3(3):113-23. PubMed ID: 6438498 [Abstract] [Full Text] [Related]